ECTRIMS 2023 | Advancements in PML genetic risk assessment

Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU), Population Bio, Oxfordshire, UK, discusses the ongoing efforts to refine a genetic test to predict the risk of progressive multifocal leukoencephalopathy (PML), emphasizing that the current test is the initial version with further refinements expected in the future. Owing to its rare occurrence, PML presents challenges for study, necessitating collaborations worldwide to amass sufficient samples. Despite this, the existing test is poised for implementation, Dr Hatchwell underscores its potential to prevent even a single case of PML, a severe condition that can result in a fatality or profound neurological impairment. The quest for an even more comprehensive test continues, and future advancements are anticipated in this critical area of research. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.